Performance-only social anxiety disorder, formally classified in DSM-5-TR as Social Anxiety Disorder with Performance-Only specifier, is a subtype where fear is restricted to performing in front of others (public speaking, musical/dramatic performance, sports competitions, professional presentations, taking exams) without significant anxiety in non-performance social interactions like dating, parties, or daily conversations. Affects 5-10% of adults; particularly common among performing artists, public speakers, athletes, students, and professionals. Distinguished from generalized SAD which affects multiple social domains.
Pathophysiology involves heightened sympathetic nervous system activation in performance contexts (anticipatory anxiety days/weeks before, peak during performance), with cognitive aspects including fear of negative evaluation, perfectionism, and rumination. Comorbidities are less common than in generalized SAD but include performance-related substance use (alcohol, beta-blockers misuse), depression, and other anxiety disorders. Risk factors: behavioral inhibition in childhood, perfectionist personality, prior negative performance experiences, family history of anxiety, and high-stakes performance demands.
Diagnosis requires DSM-5-TR criteria: marked fear/anxiety about performance situations, fear of negative evaluation, performance situations almost always provoke anxiety, avoidance or endurance with intense distress, fear out of proportion, persistent ≥6 months, clinically significant impairment, not better explained by another disorder, plus performance-only specifier. Severity assessed by Liebowitz Social Anxiety Scale (LSAS) performance subscale. Treatment is largely behavioral with situational pharmacotherapy: cognitive-behavioral therapy (CBT) with in vivo exposure (graduated exposure to performance situations), cognitive restructuring (reframing catastrophic thoughts), and skill-building (presentation skills, breathing techniques) is first-line. Beta-blockers (propranolol 10-40 mg 30-60 minutes before event, atenolol 50-100 mg) effectively block peripheral autonomic symptoms (tremor, tachycardia, sweating) without sedation; commonly used by performers. Short-term benzodiazepines (lorazepam 0.5-1 mg, alprazolam) for occasional severe events but limited duration due to dependence and impaired performance. SSRIs/SNRIs (paroxetine 20-40 mg, sertraline 50-200 mg, venlafaxine XR 75-225 mg, escitalopram 10-20 mg) for frequent performances, comorbid depression, or treatment failure with first-line approaches; effective in 60-80%. Avoidance reduction is critical to prevent disorder worsening. Mindfulness-based stress reduction, biofeedback, and group performance exposure therapy are useful adjuncts.